Skip to main content Help with accessibility Skip to main navigation

PSORIATIC ARTHRITIS: sequential use of high cost agents

CCG Approval Status:

Date Added: 28 - Nov - 2018
Body System:
Red

The Pan Mersey Area Prescribing Committee recommends the sequential use of high cost agents, adalimumab, apremilast▼, certolizumab, etanercept, golimumab, infliximab, ixekizumab▼, secukinumab▼, tofacitinib▼ and ustekinumab in the management of psoriatic arthritis (PsA) in accordance with the recommendations below, and the accompanying flowchart.

PSORIATIC ARTHRITIS and PERIPHERAL SPONDYLOARTHROPATHY: high cost drugs pathway